The six mice were imaged at 4, 24, 48, 72 and 96h post-injection (pi), and two mice were additionally imaged at 168 and 197h post-injection

The six mice were imaged at 4, 24, 48, 72 and 96h post-injection (pi), and two mice were additionally imaged at 168 and 197h post-injection. the biodistribution data. Delivered111In-labelled mAbs tumour absorbed doses were calculated SKA-31 using mouse-specific convolution dosimetry, and assimilated doses for90Y-labelled mAbs were extrapolated under the assumptions of equivalent injected activities, biological half-lives and uptake distributions as for111In. == Results == Intended for the sphere sizes investigated (volume 0. 031. 17 Mouse monoclonal to CD45/CD14 (FITC/PE) ml), the calibration element varied by a factor of 3. 7, whilst for the range of tumour masses in the mice (41232 mg), the calibration element changed by a factor of 2. 5. Comparisons between the mice imaging and the biodistribution results showed a statistically significant correlation intended for the tumour activity (r= 0. 999, P < 0. 0001) and the tumour mass calculations (r= 0. 977, P= 0. 0008), whilst no correlation was found intended for the %IA/g (r= 0. 521, P= 0. 29). Median tumour-absorbed doses per injected activity of 52 cGy/MBq (range 3669 cGy/MBq) and 649 cGy/MBq (range 441950 cGy/MBq) were delivered by111In-labelled mAbs and extrapolated for90Y-labelled mAbs, respectively. == Conclusions == This study demonstrates the need for multidisciplinary efforts to standardise imaging and dosimetry protocols in pre-clinical imaging. Accurate image quantification can improve the calculation of the activity, %IA/g and absorbed dose. Diagnostic imaging could be used to estimate the injected activities required for therapeutic studies, potentially reducing the number of animals used. Keywords: 111In, Pre-clinical, Image quantification, Partial volume effect, Dosimetry, Radiolabelled antibodies, SPECT, HER2 == Background == Molecular imaging enables minimally-invasive visualisation of molecular and cellular biological processes in living organisms. It plays an important role in cancer drug development and in monitoring disease progression and tumour response to therapeutic interventions [13]. Pet models are both cost effective and versatile and therefore have been essential in cancer research. Ex festn biodistribution and/or autoradiography studies are traditionally used to check out the uptake characteristics of novel radiolabelled tracers prior to translation to in-human clinical trials. However , these methods are limited, as they require animals to be culled at various time points and the pharmacokinetics are based on data from diverse animals at different occasions. Conversely, SPECT and PET pre-clinical imaging enables the prospect of longitudinal studies and therefore has the potential to provide quantitative measurements of radiotracer biodistribution and to reduce the number of animals required per study, which is both more cost effective and more ethical than traditional methods [4]. Complete image quantification is essential to evaluate imaging biomarkers and to accurately determine the distribution from the uptake of novel radiotracers to evaluate their toxicity and efficacy profile in small animals prior to use in human being studies. It is also necessary for dosimetry calculations and therefore SKA-31 has the potential to improve our understanding of the biological mechanisms of radiation-induced cell damage [5, 6] and to better inform the comparison of therapeutic radiotracers. The accuracy of pre-clinical molecular imaging can be degraded by several factors including attenuation, scatter, partial volume, motion and pet handling [7]. The effects of attenuation and scatter are of much less importance than in clinical imaging due to the smaller size of the subjects involved. However , multiple studies have shown that the effects can be significant intended for radionuclides SKA-31 emitting low-energy gamma rays and larger-sized rodents [813]. The spatial resolution from the imaging system also affects quantification due to the partial volume effect, particularly in the case of small animals. Nearly all studies to investigate partial volume effects in pre-clinical imaging have centered on PET [1416]. Few correction methods are available [17] and commercial imaging systems do not provide correction and/or compensation methods for partial volume effects. The aim of this study was to explore the difficulties and potential role of.